MARIZYME

Marizyme is a development-stage company dedicated to the commercialization of therapies that address the urgent need for higher mortality and costs in the acute care space. The company's first product candidates are derived from a broad intellectual property portfolio around a novel system of proteolytic enzymes called ProteomeX (previously referred to as Krillase Technology). Marizyme completed the acquisition of these assets and intends to immediately develop several product candidates that will address unmet medical needs in the acute care setting.